•
SG
SGMO
Sangamo Therapeutics, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
127.97M
Volume
4.14M
52W High
$1.40
52W Low
$0.37
Open
$0.00
Prev Close
$0.37
Day Range
0.00 - 0.00
About Sangamo Therapeutics, Inc. Common Stock
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Latest News
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends
GlobeNewswire Inc.•2h ago
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
Benzinga•Mar 18
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
GlobeNewswire Inc.•Feb 21
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
GlobeNewswire Inc.•Jan 2
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Benzinga•Dec 31
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider
GlobeNewswire Inc.•Dec 8
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology
GlobeNewswire Inc.•Nov 22
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
GlobeNewswire Inc.•Nov 6